Previous 10 | Next 10 |
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q3 2022 Earnings Call Nov 08, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q3 2022 Earnings Call Transcript
Agenus Inc. (AGEN) Q3 2022 Results Conference Call November 08, 2022 08:30 AM ET Company Participants Nico Frelick - Investor Relations Dr. Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President of Finance Dr. Steven O'Day - Chie...
Agenus press release ( NASDAQ: AGEN ): Q3 GAAP EPS of -$0.19 in-line. Revenue of $22.8M (-91.0% Y/Y) beats by $2.11M . "We ended our third quarter 2022 with a cash, cash equivalent, and short-term investment balance of $218.2 million as compared to $238.3 million a...
Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer...
Agenus ( NASDAQ: AGEN ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is -$0.18 (-125.0% Y/Y) and the consensus Revenue Estimate is $20.69M (-91.8% Y/Y). Over the last 1 year, AGEN has beaten EPS...
Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ET Company to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical experience to date and expected development plans for bote...
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high vaccine efficacy observed in severe disease (94.1%), adults aged 70-79 years (93.8%) and those with underlying comorbidities (94.6%) ...
VBI Vaccines ( NASDAQ: VBIV ) and Agenus ( NASDAQ: AGEN ) will evaluate a combination of the former's VBI-1901 and the latter's balstilimab as a combination treatment for glioblastoma . VBI-1901 is a cancer vaccine immunotherapeutic, while balstilimab...
Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022 Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in frontline Glioblastoma (GBM) patients following primary tumor resection ...
Shares of Agenus (NASDAQ: AGEN) , a clinical-stage biopharmaceutical company that specializes in immuno-oncology, saw its shares jump 18.4% on Thursday. The stock closed on Wednesday at $2.37, then opened on Thursday at $2.35, before rising to a high of $2.80 just before the market ...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...